REMARKS

In response to the restriction requirement, Applicants hereby elect Group I, claims 1-9 and 15, without traverse. Applicants note the Office's indication that upon allowance of the compound claims, it may be possible to rejoin the non-elected method claims of group II.

The Office has required restriction between:

Group I, claims 1-9 and 15, drawn to compound and pharmaceutical composition; and Group II, claims 10-14, 16-20, drawn to method of treatment.

The Office has further required an election of Species.

Applicants hereby elect Group I, claims 1-9, and 15, and in particular the species of example 4, where A is moiety II, and R¹ is thienyl:

Example 4

Applicants respectfully submit that claims 1-5, 7, 9-22 read on the elected species.

Although Applicants believe no fee is due, the Commissioner is hereby authorized to charge any fee or underpayment thereof or credit any overpayment to Deposit Account No. 26-0166.

Early reconsideration and allowance of all pending claims is respectfully requested. The examiner is requested to contact the undersigned attorney if an interview, telephonic or personal, would facilitate allowance of the claims.

Respectfully submitted, AstraZeneca

Date: September 10, 2008 By: /Michael A. Patané/, Reg. No. 42,982